JP2018516969A - Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 - Google Patents

Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 Download PDF

Info

Publication number
JP2018516969A
JP2018516969A JP2017564421A JP2017564421A JP2018516969A JP 2018516969 A JP2018516969 A JP 2018516969A JP 2017564421 A JP2017564421 A JP 2017564421A JP 2017564421 A JP2017564421 A JP 2017564421A JP 2018516969 A JP2018516969 A JP 2018516969A
Authority
JP
Japan
Prior art keywords
antibody
cxcr4
antigen
specifically binds
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017564421A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516969A5 (OSRAM
Inventor
ジョセフィン・エム・カルダレッリ
ウェンディ・エル・クレメンス
グレン・エス・クルーグ
ダニエル・イー・ロペス・デ・メネゼス
チン・パン
ポール・ディ・ポナス
ジャン・ビアレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2018516969A publication Critical patent/JP2018516969A/ja
Publication of JP2018516969A5 publication Critical patent/JP2018516969A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017564421A 2015-06-12 2016-06-13 Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置 Withdrawn JP2018516969A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562174931P 2015-06-12 2015-06-12
US62/174,931 2015-06-12
PCT/US2016/037207 WO2016201425A1 (en) 2015-06-12 2016-06-13 Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways

Publications (2)

Publication Number Publication Date
JP2018516969A true JP2018516969A (ja) 2018-06-28
JP2018516969A5 JP2018516969A5 (OSRAM) 2019-07-18

Family

ID=56194616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564421A Withdrawn JP2018516969A (ja) 2015-06-12 2016-06-13 Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置

Country Status (9)

Country Link
US (1) US20180179282A1 (OSRAM)
EP (1) EP3307778A1 (OSRAM)
JP (1) JP2018516969A (OSRAM)
CN (1) CN108026173A (OSRAM)
BR (1) BR112017026189A2 (OSRAM)
CA (1) CA2989144A1 (OSRAM)
EA (1) EA201792522A1 (OSRAM)
MX (1) MX2017015811A (OSRAM)
WO (1) WO2016201425A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528030A (ja) * 2019-01-07 2022-06-08 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101607288B1 (ko) * 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
KR102702287B1 (ko) * 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CA3008272A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3008279A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHOD FOR THE TREATMENT OF CANCER
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3045302A1 (en) * 2016-11-29 2018-06-07 Health Research, Inc. Methods and compositions for cancer therapy
EP3600395A4 (en) * 2017-03-23 2021-05-05 The General Hospital Corporation BLOCKING OF CXCR4 / CXCR7 AND TREATMENT OF HUMAN PAPILLOMAVIRUS-ASSOCIATED DISEASE
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
CN113150068B (zh) * 2017-09-20 2023-04-04 尚华医药科技(江西)有限公司 一种肽类化合物、其应用及含其的组合物
CN111465613A (zh) * 2017-11-07 2020-07-28 X4 制药有限公司 癌症生物标志物及其使用方法
ES2973728T3 (es) * 2018-03-13 2024-06-24 Fundacion Para La Investigacion Biomedica Del Hospital Univ La Paz Anticuerpo anti-CXCR4 combinado con linfocitos citolíticos naturales activados y expandidos para inmunoterapia contra el cáncer
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US12291570B2 (en) * 2018-10-17 2025-05-06 Biolinerx Ltd. Treatment of metastatic pancreatic adenocarcinoma
CN113164599B (zh) * 2018-12-24 2023-08-01 正大天晴药业集团股份有限公司 抗pd-l1单克隆抗体治疗癌症的用途
CA3133460A1 (en) * 2019-03-22 2020-10-01 Sumitomo Dainippon Pharma Oncology, Inc. Compositions comprising pkm2 modulators and methods of treatment using the same
EP4117662A4 (en) 2020-03-10 2024-04-03 X4 Pharmaceuticals, Inc. METHODS OF TREATING NEUTROPENIA
AR129061A1 (es) 2022-04-13 2024-07-10 Genentech Inc Composiciones farmacéuticas de mosunetuzumab y métodos de uso
AU2023253705A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of therapeutic proteins and methods of use
TW202400659A (zh) * 2022-05-04 2024-01-01 美商詹努克斯治療有限公司 經腫瘤活化之靶向ｃｄ２８及ｐｄ－ｌ１之多特異性抗體及其使用方法
CN115487146B (zh) * 2022-10-28 2023-07-18 宁夏医科大学 一种阻断cxcr4/pd-l1双信号的三药共递送纳米体系及其制备方法和应用
CN120282799A (zh) * 2022-12-07 2025-07-08 宜明昂科生物医药技术（上海）股份有限公司 使用cd24抗体和pd-1-pd-l1通路阻断抗体的癌症联合疗法
CN120813375A (zh) * 2023-01-30 2025-10-17 凯玛布有限公司 抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
WO2008018641A1 (en) 2006-08-11 2008-02-14 Ono Pharmaceutical Co., Ltd. Monoclonal antibodies against stromal derived factor-1 (sdf-1)
AR063086A1 (es) * 2006-10-02 2008-12-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y usos de los mismos
FR2915102B1 (fr) 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
EP2535354B1 (en) 2007-06-18 2017-01-11 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US7892546B2 (en) 2008-05-14 2011-02-22 Eli Lilly And Company Anti-CXCR4 antibodies
KR20100133012A (ko) 2008-05-14 2010-12-20 일라이 릴리 앤드 캄파니 항-ｃｘｃｒ4 항체
US20110159023A1 (en) * 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
EP2172485A1 (en) 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
WO2013013025A2 (en) 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
MX357100B (es) 2011-11-09 2018-06-26 Bristol Myers Squibb Co Tratamiento de neoplasias hematologicas con un anticuerpo anti-cxcr4.
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
KR102702287B1 (ko) 2012-05-15 2024-09-04 브리스톨-마이어스 스큅 컴퍼니 Pd-1/pd-l1 신호전달을 방해하는 것에 의한 암 면역요법
KR102410078B1 (ko) 2012-05-31 2022-06-22 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
CN104968364A (zh) 2012-12-03 2015-10-07 百时美施贵宝公司 强化免疫调变性Fc融合蛋白的抗癌活性
EP3027653A2 (en) 2013-08-02 2016-06-08 Pfizer Inc Anti-cxcr4 antibodies and antibody-drug conjugates
JP2016527303A (ja) * 2013-08-05 2016-09-08 ケンブリッジ エンタープライズ リミテッド がん免疫療法におけるｃｘｃｒ４シグナル伝達の阻害

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022528030A (ja) * 2019-01-07 2022-06-08 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用
JP7587505B2 (ja) 2019-01-07 2024-11-20 トーマス・ジェファーソン・ユニバーシティ 多機能性融合タンパク質及びその使用
US12497439B2 (en) 2019-01-07 2025-12-16 Thomas Jefferson University Multi-functional fusion proteins and uses thereof

Also Published As

Publication number Publication date
MX2017015811A (es) 2018-04-10
WO2016201425A9 (en) 2017-01-19
EA201792522A1 (ru) 2018-05-31
BR112017026189A2 (pt) 2018-08-14
US20180179282A1 (en) 2018-06-28
CA2989144A1 (en) 2016-12-15
EP3307778A1 (en) 2018-04-18
WO2016201425A1 (en) 2016-12-15
CN108026173A (zh) 2018-05-11

Similar Documents

Publication Publication Date Title
JP2018516969A (ja) Ｐｄ−１およびｃｘｃｒ４シグナル伝達経路の組合せ遮断による癌の処置
US20250011466A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
US20220298243A1 (en) Anti-pd-1 antibody in combination with an anti-cd30 antibody in cancer treatment
JP2022068352A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体の組合せを用いる肺癌の処置法
CN106573977B (zh) 针对ceacam1的人源化抗体
CN104470949A (zh) 通过破坏pd-1/pd-l1信号传输的免疫治疗
JP2017507155A (ja) 抗ｐｄ−１抗体と他の抗癌剤の組合せを使用する腎癌の処置
US20230279096A1 (en) Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
US20240218066A1 (en) Use of anti-pd-1 antibody in combination with first-line chemotherapy in treatment of advanced non-small cell lung cancer
KR20240038008A (ko) 암 치료 방법 및 조성물
JP2024511977A (ja) 抗ｉｌｔ３抗体によるがんの治療方法

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20180227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190612

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190612

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20190930